世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
 Biologics Contract Manufacturing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)
The biologics contract manufacturing market is on an impressive upward trajectory, driven by the rising demand for novel biologics, biosimilars, and personalized medicines. With increasing outsourc... もっと見る
※当ページの内容はウェブ更新時の情報です。
SummaryThe biologics contract manufacturing market is on an impressive upward trajectory, driven by the rising demand for novel biologics, biosimilars, and personalized medicines. With increasing outsourcing trends and the rapid advancement of biopharmaceutical technologies, contract development and manufacturing organizations (CDMOs) are playing a pivotal role in drug development and commercialization.Market Insights According to industry analysis, the global biologics contract manufacturing market is projected to grow from an estimated USD 21.9 billion in 2025 to USD 40.2 billion by 2032. This expansion represents a CAGR of 9.03% over the forecast period. The growing complexity of biologics, the need for specialized manufacturing platforms, and the push for reduced time-to-market are driving organizations to seek the support of experienced CDMOs. Key Market Drivers • Robust Biologics Pipeline: The global biologics pipeline remains strong, with more than 1,500 biomolecules under clinical evaluation across various therapeutic areas. This steady growth supports continued outsourcing. • Limited In-House Capacity: Many large pharmaceutical companies face infrastructure and capacity constraints, prompting them to outsource development and production processes. • Next-Gen Therapeutics: There is an increasing shift toward next-generation biotherapeutics, including antibody-drug conjugates and bispecific antibodies, driving demand for innovative manufacturing solutions. • Technological Advancements: Single-use bioreactor systems and modular manufacturing units are providing increased flexibility, cost efficiency, and scalability. Business Opportunity As biopharmaceutical companies seek to enhance speed-to-market and cost efficiency, CDMOs offering integrated services are witnessing a surge in demand. Outsourcing to a single partner from molecule development to final drug product helps streamline timelines and ensures quality consistency. Partnerships and acquisitions are enabling CDMOs to expand capabilities and geographic reach. For example, Lonza and AGC Biologics have both made strategic acquisitions to expand their end-to-end service offerings in recent years. The outsourcing trend is also being driven by biosimilar development, particularly in oncology and autoimmune diseases, where biologics dominate therapeutic approaches. Additionally, increasing adoption of mammalian cell platforms for protein production continues to shape the business Analysis. Regional Analysis • United States: The U.S. dominates the North American market, attributed to a strong biotech ecosystem, high R&D expenditure, and a favorable regulatory environment. A growing number of CDMOs, research institutions, and startup collaborations are also fueling growth. • Germany: In Europe, Germany is emerging as a key market with a strong clinical research infrastructure and increasing outsourcing of biopharma research to control operational costs. • China: In Asia, China is making significant strides due to a large skilled workforce and government support for biopharmaceutical innovation. Partnerships between multinational pharma companies and local CDMOs are boosting regional development. Key Players Leading CDMOs in the biologics contract manufacturing market include: • Lonza Group AG • Samsung Biologics • WuXi Biologics (Cayman) Inc. • Fujifilm Diosynth Biotechnologies • Boehringer Ingelheim (BioXcellence) • AbbVie CM • Thermo Fisher Scientific Inc. (Patheon N.V.) • Emergent BioSolutions Inc. • Catalent Inc. • AGC Biologics • Avid Bioservices • KBI Biopharma • Ajinomoto Bio-Pharma • Abzena plc • Rentschler Biotechnologie GmbH • Therapure Biopharma Inc. • ProBioGen AG • Novasep These organizations are expanding their manufacturing capacities, introducing new platforms, and entering strategic collaborations to strengthen their market presence. Market Challenges Despite the positive outlook, challenges such as stringent regulatory requirements, high initial setup costs, and a shortage of skilled professionals in emerging economies hinder market growth. Moreover, supply chain vulnerabilities and inspection backlogs continue to impact timely production and delivery. Segmentation By Product • Monoclonal Antibodies • Recombinant Proteins • Vaccines • Insulin • Interferons • Growth Factors • Others By Platform • Mammalian • Microbial By Therapeutic Area • Oncology • Autoimmune Diseases • Metabolic Diseases • Cardiovascular Diseases • Infectious Diseases • Neurology • Ophthalmology • Respiratory Disorders • Others By Application • Commercial • Clinical By Region • North America • Europe • Latin America • East Asia • South Asia • Oceania • Middle East & Africa Table of Contents1. Executive Summary1.1. Global Biologics Contract Manufacturing Demand Market Snapshot 1.2. Future Projections 1.3. Key Market Trends 1.4. Regional Snapshot, by Value and Volume, 2025 1.5. Analyst Recommendations 2. Market Overview 2.1. Market Definitions and Segmentations 2.2. Market Dynamics 2.2.1. Drivers 2.2.2. Restraints 2.2.3. Market Opportunities 2.3. Value Chain Analysis 2.4. Porter’s Five Forces Analysis 2.5. COVID-19 Impact Analysis 2.5.1. Supply 2.5.2. Demand 2.6. Impact of Ukraine-Russia Conflict 2.7. Economic Overview 2.7.1. World Economic Projections 2.8. PESTLE Analysis 3. Production Output and Trade Statistics, 2019-2024 3.1. Global Biologics Contract Manufacturing Demand Market Production Output, by Region, Value (US$ Bn) and Volume (KL), 2019-2024 3.1.1. North America 3.1.2. Europe 3.1.3. Asia Pacific 3.1.4. Latin America 3.1.5. Middle East and Africa 4. Price Analysis, 2019-2024 4.1. Global Average Price Analysis, by Product, US$ Per Unit, 2019-2024 4.2. Prominent Factor Affecting Protective Sunglasses Prices 4.3. Global Average Price Analysis, by Region, US$ Per Unit 5. Global Biologics Contract Manufacturing Demand Market Outlook, 2019-2032 5.1. Global Biologics Contract Manufacturing Demand Market Outlook, by Product, Value (US$ Bn) and Volume (KL), 2019-2032 5.1.1. Key Highlights 5.1.1.1. Monoclonal Antibodies 5.1.1.2. Recombinant Proteins 5.1.1.3. Vaccines 5.1.1.4. Insulin 5.1.1.5. Interferons 5.1.1.6. Growth Factors 5.1.1.7. Others 5.2. Global Biologics Contract Manufacturing Demand Market Outlook, by Platform, Value (US$ Bn) and Volume (KL), 2019-2032 5.2.1. Key Highlights 5.2.1.1. Mammalian 5.2.1.2. Microbial 5.3. Global Biologics Contract Manufacturing Demand Market Outlook, by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2032 5.3.1. Key Highlights 5.3.1.1. Oncology 5.3.1.2. Autoimmune Disease 5.3.1.3. Metabolic Disease 5.3.1.4. Opthalmology 5.3.1.5. Cardiovascular Disease 5.3.1.6. Infectious Disease 5.3.1.7. Neurology 5.3.1.8. Respiratory Disorder 5.3.1.9. Others 5.4. Global Biologics Contract Manufacturing Demand Market Outlook, by Application, Value (US$ Bn) and Volume (KL), 2019-2032 5.4.1. Key Highlights 5.4.1.1. Commercial 5.4.1.2. Clinical 5.5. Global Biologics Contract Manufacturing Demand Market Outlook, by Region, Value (US$ Bn) and Volume (KL), 2019-2032 5.5.1. Key Highlights 5.5.1.1. North America 5.5.1.2. Europe 5.5.1.3. Asia Pacific 5.5.1.4. Latin America 5.5.1.5. Middle East & Africa 6. North America Biologics Contract Manufacturing Demand Market Outlook, 2019-2032 6.1. North America Biologics Contract Manufacturing Demand Market Outlook, by Product, Value (US$ Bn) and Volume (KL), 2019-2032 6.1.1. Key Highlights 6.1.1.1. Monoclonal Antibodies 6.1.1.2. Recombinant Proteins 6.1.1.3. Vaccines 6.1.1.4. Insulin 6.1.1.5. Interferons 6.1.1.6. Growth Factors 6.1.1.7. Others 6.2. North America Biologics Contract Manufacturing Demand Market Outlook, by Platform, Value (US$ Bn) and Volume (KL), 2019-2032 6.2.1. Key Highlights 6.2.1.1. Mammalian 6.2.1.2. Microbial 6.3. North America Biologics Contract Manufacturing Demand Market Outlook, by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2032 6.3.1. Key Highlights 6.3.1.1. Oncology 6.3.1.2. Autoimmune Disease 6.3.1.3. Metabolic Disease 6.3.1.4. Opthalmology 6.3.1.5. Cardiovascular Disease 6.3.1.6. Infectious Disease 6.3.1.7. Neurology 6.3.1.8. Respiratory Disorder 6.3.1.9. Others 6.4. North America Biologics Contract Manufacturing Demand Market Outlook, by Application, Value (US$ Bn) and Volume (KL), 2019-2032 6.4.1. Key Highlights 6.4.1.1. Commercial 6.4.1.2. Clinical 6.5. North America Biologics Contract Manufacturing Demand Market Outlook, by Country, Value (US$ Bn) and Volume (KL), 2019-2032 6.5.1. Key Highlights 6.5.1.1. U.S. Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032 6.5.1.2. U.S. Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032 6.5.1.3. U.S. Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032 6.5.1.4. U.S. Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032 6.5.1.5. Canada Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032 6.5.1.6. Canada Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032 6.5.1.7. Canada Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032 6.5.1.8. Canada Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032 6.5.2. BPS Analysis/Market Attractiveness Analysis 7. Europe Biologics Contract Manufacturing Demand Market Outlook, 2019-2032 7.1. Europe Biologics Contract Manufacturing Demand Market Outlook, by Product, Value (US$ Bn) and Volume (KL), 2019-2032 7.1.1. Key Highlights 7.1.1.1. Monoclonal Antibodies 7.1.1.2. Recombinant Proteins 7.1.1.3. Vaccines 7.1.1.4. Insulin 7.1.1.5. Interferons 7.1.1.6. Growth Factors 7.1.1.7. Others 7.2. Europe Biologics Contract Manufacturing Demand Market Outlook, by Platform, Value (US$ Bn) and Volume (KL), 2019-2032 7.2.1. Key Highlights 7.2.1.1. Mammalian 7.2.1.2. Microbial 7.3. Europe Biologics Contract Manufacturing Demand Market Outlook, by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2032 7.3.1. Key Highlights 7.3.1.1. Oncology 7.3.1.2. Autoimmune Disease 7.3.1.3. Metabolic Disease 7.3.1.4. Opthalmology 7.3.1.5. Cardiovascular Disease 7.3.1.6. Infectious Disease 7.3.1.7. Neurology 7.3.1.8. Respiratory Disorder 7.3.1.9. Others 7.4. Europe Biologics Contract Manufacturing Demand Market Outlook, by Application, Value (US$ Bn) and Volume (KL), 2019-2032 7.4.1. Key Highlights 7.4.1.1. Commercial 7.4.1.2. Clinical 7.5. Europe Biologics Contract Manufacturing Demand Market Outlook, by Country, Value (US$ Bn) and Volume (KL), 2019-2032 7.5.1. Key Highlights 7.5.1.1. Germany Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032 7.5.1.2. Germany Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032 7.5.1.3. Germany Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032 7.5.1.4. Germany Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032 7.5.1.5. U.K. Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032 7.5.1.6. U.K. Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032 7.5.1.7. U.K. Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032 7.5.1.8. U.K. Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032 7.5.1.9. France Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032 7.5.1.10. France Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032 7.5.1.11. France Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032 7.5.1.12. France Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032 7.5.1.13. Italy Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032 7.5.1.14. Italy Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032 7.5.1.15. Italy Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032 7.5.1.16. Italy Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032 7.5.1.17. Turkey Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032 7.5.1.18. Turkey Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032 7.5.1.19. Turkey Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032 7.5.1.20. Turkey Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032 7.5.1.21. Russia Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032 7.5.1.22. Russia Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032 7.5.1.23. Russia Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032 7.5.1.24. Russia Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032 7.5.1.25. Rest of Europe Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032 7.5.1.26. Rest of Europe Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032 7.5.1.27. Rest of Europe Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032 7.5.1.28. Rest of Europe Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032 7.5.2. BPS Analysis/Market Attractiveness Analysis 8. Asia Pacific Biologics Contract Manufacturing Demand Market Outlook, 2019-2032 8.1. Asia Pacific Biologics Contract Manufacturing Demand Market Outlook, by Product, Value (US$ Bn) and Volume (KL), 2019-2032 8.1.1. Key Highlights 8.1.1.1. Monoclonal Antibodies 8.1.1.2. Recombinant Proteins 8.1.1.3. Vaccines 8.1.1.4. Insulin 8.1.1.5. Interferons 8.1.1.6. Growth Factors 8.1.1.7. Others 8.2. Asia Pacific Biologics Contract Manufacturing Demand Market Outlook, by Platform, Value (US$ Bn) and Volume (KL), 2019-2032 8.2.1. Key Highlights 8.2.1.1. Mammalian 8.2.1.2. Microbial 8.3. Asia Pacific Biologics Contract Manufacturing Demand Market Outlook, by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2032 8.3.1. Key Highlights 8.3.1.1. Oncology 8.3.1.2. Autoimmune Disease 8.3.1.3. Metabolic Disease 8.3.1.4. Opthalmology 8.3.1.5. Cardiovascular Disease 8.3.1.6. Infectious Disease 8.3.1.7. Neurology 8.3.1.8. Respiratory Disorder 8.3.1.9. Others 8.4. Asia Pacific Biologics Contract Manufacturing Demand Market Outlook, by Application, Value (US$ Bn) and Volume (KL), 2019-2032 8.4.1. Key Highlights 8.4.1.1. Commercial 8.4.1.2. Clinical 8.5. Asia Pacific Biologics Contract Manufacturing Demand Market Outlook, by Country, Value (US$ Bn) and Volume (KL), 2019-2032 8.5.1. Key Highlights 8.5.1.1. China Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032 8.5.1.2. China Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032 8.5.1.3. China Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032 8.5.1.4. China Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032 8.5.1.5. Japan Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032 8.5.1.6. Japan Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032 8.5.1.7. Japan Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032 8.5.1.8. Japan Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032 8.5.1.9. South Korea Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032 8.5.1.10. South Korea Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032 8.5.1.11. South Korea Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032 8.5.1.12. South Korea Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032 8.5.1.13. India Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032 8.5.1.14. India Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032 8.5.1.15. India Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032 8.5.1.16. India Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032 8.5.1.17. Southeast Asia Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032 8.5.1.18. Southeast Asia Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032 8.5.1.19. Southeast Asia Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032 8.5.1.20. Southeast Asia Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032 8.5.1.21. Rest of Asia Pacific Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032 8.5.1.22. Rest of Asia Pacific Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032 8.5.1.23. Rest of Asia Pacific Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032 8.5.1.24. Rest of Asia Pacific Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032 8.5.2. BPS Analysis/Market Attractiveness Analysis 9. Latin America Biologics Contract Manufacturing Demand Market Outlook, 2019-2032 9.1. Latin America Biologics Contract Manufacturing Demand Market Outlook, by Product, Value (US$ Bn) and Volume (KL), 2019-2032 9.1.1. Key Highlights 9.1.1.1. Monoclonal Antibodies 9.1.1.2. Recombinant Proteins 9.1.1.3. Vaccines 9.1.1.4. Insulin 9.1.1.5. Interferons 9.1.1.6. Growth Factors 9.1.1.7. Others 9.2. Latin America Biologics Contract Manufacturing Demand Market Outlook, by Platform, Value (US$ Bn) and Volume (KL), 2019-2032 9.2.1.1. Mammalian 9.2.1.2. Microbial 9.3. Latin America Biologics Contract Manufacturing Demand Market Outlook, by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2032 9.3.1. Key Highlights 9.3.1.1. Oncology 9.3.1.2. Autoimmune Disease 9.3.1.3. Metabolic Disease 9.3.1.4. Opthalmology 9.3.1.5. Cardiovascular Disease 9.3.1.6. Infectious Disease 9.3.1.7. Neurology 9.3.1.8. Respiratory Disorder 9.3.1.9. Others 9.4. Latin America Biologics Contract Manufacturing Demand Market Outlook, by Application, Value (US$ Bn) and Volume (KL), 2019-2032 9.4.1. Key Highlights 9.4.1.1. Commercial 9.4.1.2. Clinical 9.5. Latin America Biologics Contract Manufacturing Demand Market Outlook, by Country, Value (US$ Bn) and Volume (KL), 2019-2032 9.5.1. Key Highlights 9.5.1.1. Brazil Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032 9.5.1.2. Brazil Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032 9.5.1.3. Brazil Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032 9.5.1.4. Brazil Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032 9.5.1.5. Mexico Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032 9.5.1.6. Mexico Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032 9.5.1.7. Mexico Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032 9.5.1.8. Mexico Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032 9.5.1.9. Argentina Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032 9.5.1.10. Argentina Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032 9.5.1.11. Argentina Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032 9.5.1.12. Argentina Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032 9.5.1.13. Rest of Latin America Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032 9.5.1.14. Rest of Latin America Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032 9.5.1.15. Rest of Latin America Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032 9.5.1.16. Rest of Latin America Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032 9.5.2. BPS Analysis/Market Attractiveness Analysis 10. Middle East & Africa Biologics Contract Manufacturing Demand Market Outlook, 2019-2032 10.1. Middle East & Africa Biologics Contract Manufacturing Demand Market Outlook, by Product, Value (US$ Bn) and Volume (KL), 2019-2032 10.1.1. Key Highlights 10.1.1.1. Monoclonal Antibodies 10.1.1.2. Recombinant Proteins 10.1.1.3. Vaccines 10.1.1.4. Insulin 10.1.1.5. Interferons 10.1.1.6. Growth Factors 10.1.1.7. Others 10.2. Middle East & Africa Biologics Contract Manufacturing Demand Market Outlook, by Platform, Value (US$ Bn) and Volume (KL), 2019-2032 10.2.1. Key Highlights 10.2.1.1. Mammalian 10.2.1.2. Microbial 10.3. Middle East & Africa Biologics Contract Manufacturing Demand Market Outlook, by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2032 10.3.1. Key Highlights 10.3.1.1. Oncology 10.3.1.2. Autoimmune Disease 10.3.1.3. Metabolic Disease 10.3.1.4. Opthalmology 10.3.1.5. Cardiovascular Disease 10.3.1.6. Infectious Disease 10.3.1.7. Neurology 10.3.1.8. Respiratory Disorder 10.3.1.9. Others 10.4. Middle East & Africa Biologics Contract Manufacturing Demand Market Outlook, by Application, Value (US$ Bn) and Volume (KL), 2019-2032 10.4.1. Key Highlights 10.4.1.1. Commercial 10.4.1.2. Clinical 10.5. Middle East & Africa Biologics Contract Manufacturing Demand Market Outlook, by Country, Value (US$ Bn) and Volume (KL), 2019-2032 10.5.1. Key Highlights 10.5.1.1. GCC Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032 10.5.1.2. GCC Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032 10.5.1.3. GCC Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032 10.5.1.4. GCC Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032 10.5.1.5. South Africa Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032 10.5.1.6. South Africa Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032 10.5.1.7. South Africa Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032 10.5.1.8. South Africa Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032 10.5.1.9. Egypt Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032 10.5.1.10. Egypt Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032 10.5.1.11. Egypt Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032 10.5.1.12. Egypt Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032 10.5.1.13. Nigeria Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032 10.5.1.14. Nigeria Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032 10.5.1.15. Nigeria Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032 10.5.1.16. Nigeria Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032 10.5.1.17. Rest of Middle East & Africa Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032 10.5.1.18. Rest of Middle East & Africa Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032 10.5.1.19. Rest of Middle East & Africa Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032 10.5.1.20. Rest of Middle East & Africa Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032 10.5.2. BPS Analysis/Market Attractiveness Analysis 11. Competitive Landscape 11.1. Artery Type vs Indication Heatmap 11.2. Manufacturer vs Indication Heatmap 11.3. Company Market Share Analysis, 2025 11.4. Competitive Dashboard 11.5. Company Profiles 11.5.1. Samsung Biologics 11.5.1.1. Company Overview 11.5.1.2. Product Portfolio 11.5.1.3. Financial Overview 11.5.1.4. Business Strategies and Development 11.5.2. BioXcellence (Boehringer Ingelheim) 11.5.2.1. Company Overview 11.5.2.2. Product Portfolio 11.5.2.3. Financial Overview 11.5.2.4. Business Strategies and Development 11.5.3. Lonza Group AG 11.5.3.1. Company Overview 11.5.3.2. Product Portfolio 11.5.3.3. Financial Overview 11.5.3.4. Business Strategies and Development 11.5.4. Fujifilm Diosynth Biotechnologies 11.5.4.1. Company Overview 11.5.4.2. Product Portfolio 11.5.4.3. Financial Overview 11.5.4.4. Business Strategies and Development 11.5.5. AbbVie CM (AbbVie Inc.) 11.5.5.1. Company Overview 11.5.5.2. Product Portfolio 11.5.5.3. Financial Overview 11.5.5.4. Business Strategies and Development 11.5.6. WuXi Biologics (Cayman) Inc. 11.5.6.1. Company Overview 11.5.6.2. Product Portfolio 11.5.6.3. Financial Overview 11.5.6.4. Business Strategies and Development 11.5.7. AGC Biologics 11.5.7.1. Company Overview 11.5.7.2. Product Portfolio 11.5.7.3. Financial Overview 11.5.7.4. Business Strategies and Development 11.5.8. Patheon N.V. (Thermo Fisher Scientific Inc.) 11.5.8.1. Company Overview 11.5.8.2. Product Portfolio 11.5.8.3. Financial Overview 11.5.8.4. Business Strategies and Development 11.5.9. Emergent BioSolutions Inc. 11.5.9.1. Company Overview 11.5.9.2. Product Portfolio 11.5.9.3. Financial Overview 11.5.9.4. Business Strategies and Development 11.5.10. Ajinomoto Bio-Pharma 11.5.10.1. Company Overview 11.5.10.2. Product Portfolio 11.5.10.3. Financial Overview 11.5.10.4. Business Strategies and Development 11.5.11. Avid Bioservices, Inc. 11.5.11.1. Company Overview 11.5.11.2. Product Portfolio 11.5.11.3. Financial Overview 11.5.11.4. Business Strategies and Development 11.5.12. KBI Biopharma 11.5.12.1. Company Overview 11.5.12.2. Product Portfolio 11.5.12.3. Financial Overview 11.5.12.4. Business Strategies and Development 11.5.13. Rentschler Biotechnologie GmbH 11.5.13.1. Company Overview 11.5.13.2. Product Portfolio 11.5.13.3. Financial Overview 11.5.13.4. Business Strategies and Development 11.5.14. Merck KGaA 11.5.14.1. Company Overview 11.5.14.2. Product Portfolio 11.5.14.3. Financial Overview 11.5.14.4. Business Strategies and Development 11.5.15. Catalent Inc. 11.5.15.1. Company Overview 11.5.15.2. Product Portfolio 11.5.15.3. Financial Overview 11.5.15.4. Business Strategies and Development 11.5.16. Therapure Biopharma Inc. 11.5.16.1. Company Overview 11.5.16.2. Product Portfolio 11.5.16.3. Financial Overview 11.5.16.4. Business Strategies and Development 11.5.17. Novasep 11.5.17.1. Company Overview 11.5.17.2. Product Portfolio 11.5.17.3. Financial Overview 11.5.17.4. Business Strategies and Development 11.5.18. Abzena plc. 11.5.18.1. Company Overview 11.5.18.2. Product Portfolio 11.5.18.3. Financial Overview 11.5.18.4. Business Strategies and Development 11.5.19. ProBioGen AG 11.5.19.1. Company Overview 11.5.19.2. Product Portfolio 11.5.19.3. Financial Overview 11.5.19.4. Business Strategies and Development 12. Appendix 12.1. Research Methodology 12.2. Report Assumptions 12.3. Acronyms and Abbreviations
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（医療IT）の最新刊レポート
Fairfield Market Research社の ヘルスケアIT分野 での最新刊レポート
本レポートと同じKEY WORD（biologics）の最新刊レポートよくあるご質問Fairfield Market Research社はどのような調査会社ですか?Fairfield Market Researchでは、最新かつ最も関連性の高い市場データと洞察に満ちた詳細なレポートを発行しています。広範囲にわたり、業界動向や市場ベースのデータを含んでおり、顧客が... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
|
